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Abstract: Searching for depigmenting agents from natural sources has become a new direction 
in the cosmetic industry as natural products are generally perceived as relatively safer.  
In our previous study, selected Chinese medicines traditionally used to treat hyperpigmentation 
were tested for anti-hyperpigmentary effects using a melan-a cell culture model. Among 
the tested chemical compounds, 4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol were 
found to possess hypopigmentary effects. Western blot analysis, reverse transcriptase 
polymerase chain reaction (RT-PCR), cyclic adenosine monophosphate (cAMP) assay, 
protein kinase A (PKA) activity assay, tyrosinase inhibition assay and lipid peroxidation 
inhibition assay were performed to reveal the underlying cellular and molecular mechanisms 
of the hypopigmentary effects. 4-Ethylresorcinol and 4-ethylphenol attenuated mRNA and 
protein expression of tyrosinase-related protein (TRP)-2, and possessed antioxidative effect  
by inhibiting lipid peroxidation. 1-Tetradecanol was able to attenuate protein expression of 
tyrosinase. The hypopigmentary actions of 4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol 
were associated with regulating downstream proteins along the PKA pathway.  
4-Ethylresorcinol was more effective in inhibiting melanin synthesis when compared to  
4-ethylphenol and 1-tetradecanol. 
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1. Introduction 
Melanogenesis forms a natural protective system against UV-induced damage on the skin. 
However, over production of melanin can lead to hyperpigmentary disorders such as freckles, chloasma 
and lentigines. Hyperpigmentation is one of the most common cosmetic problems affecting many 
people around the world and the demands for skin whitening agents to combat hyperpigmantary 
disorders remain substantial. 
Melanogenesis is a complex biochemical process involving a number of cell signaling pathways.  
To understand the pharmacological mechanisms of potential anti-hyperpigmentary compounds, it is 
necessary to study their effects on the signaling pathways within the melanocytes, and the cross-talk of 
those pathways. The most frequently studied melanogenic pathways include protein kinase A (PKA), 
p38 mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) and extracellular 
signal-regulated kinase (ERK) pathways. 
In the PKA cascade, cyclic adenosine monophosphate (cAMP), which is converted from adenosine 
triphosphate, first stimulates PKA [1]. Activated PKA then phosphorylates and activates cAMP 
response element binding protein (CREB) which in turn binds to the cAMP response element located 
at the M promoter of the microphthalmia-associated transcription factor (MITF) gene [2]. The elevation 
of MITF expression stimulates the transcription and translation of tyrosinase, tyrosinase-related  
protein (TRP)-1 and TRP-2 [3]. These three proteins are localized in the melanosomal membrane [4]. 
Their activation promotes the onset of melanogenesis. Tyrosinase is the rate-limiting enzyme [4,5]  
and participates in the first reaction step of melanogenesis in the melanosome which catalyses  
tyrosine hydroxylation. It also catalyses 3,4-dihydroxyphenylalanine (DOPA) dehydrogenation and  
5,6-dihydroxyindole dehydrogenation [6]. TRP-1 acts as a 5,6-dihydroxyindole-2-carboxylic acid 
(DHICA) oxidase which converts DHICA to indole-quinones [7–9]. TRP-2 acts as a dopachrome 
tautomerase that catalyses the tautomerization of dopachrome to DHICA [10,11]. 
In the p38 MAPK cascade, active PKA stimulates p38 MAPK, then p38 MAPK phosphorylates  
and activates MITF [12,13], subsequently initiating melanogenesis. On the other hand, in the PI3K 
cascade, cAMP inhibits PI3K and Akt [14,15], then glycogen synthase kinase (GSK) 3β is  
activated [16]. GSK 3β phosphorylates MITF and enhances the binding of MITF to the M-box of the 
tyrosinase promoter, thereby stimulating tyrosinase expression [17]. GSK 3β also phosphorylates  
Tau [18]. Furthermore, in the ERK cascade, cAMP activates Ras, Raf, MAPK kinase (MEK), ERK 
and then ribosomal S6 kinase (RSK) [19–21]. ERK and RSK initiate the degradation of MITF, 
resulting in the attenuation of melanogenesis [22–25]. The pathway acts as a feedback mechanism to 
avoid melanin over production [21]. 
A number of hypopigmentary therapies are now available for hyperpigmentary disorders including 
laser therapy, plastic surgery and whitening chemical agents. An ideal hypopigmentary agent should 
have the ability to inhibit the activity of the rate-limiting enzyme tyrosinase and/or attenuate the expression 
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of any proteins in the respective melanogenic pathways. Therefore, compounds that exert potent 
depigmenting effect at both enzymatic and cellular levels continue to be investigated. Searching for 
effective hypopigmentary compounds from natural sources is a hot pursuit in the cosmetic industry 
since natural products are generally perceived by consumers as free from, or having few side-effects. 
In our previous study, we employed melan-a, a non-tumorigenic cell line, as an in vitro system to 
screen a number of selected Chinese herbs for their potential inhibition on melanogenesis. We also reported 
the development and validation of an assay which involves the combination of sulphorhodamine B (SRB) 
and melanin assays, and the application of this combined assay on the screening of herbal extracts  
and natural compounds for hypopigmentary agents [26]. Among the tested chemical compounds,  
4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol (Figure 1) were found to elicit inhibitory effect on 
melanin synthesis in melan-a cells. As a continuation of our endeavors to develop hypopigmentary 
pharmaceutical agents, in the present follow-up study, we aimed to evaluate the underlying biochemical 
mechanisms of these effective compounds using a panel of biochemical assays including Western blot 
analysis, reverse transcriptase polymerase chain reaction (RT-PCR), cAMP assay, PKA activity assay, 
tyrosinase inhibition assay and lipid peroxidation inhibition assay. 
Figure 1. The chemical structures of (A) 4-ethylresorcinol; (B) 4-ethylphenol; and  
(C) 1-tetradecanol which elicit anti-hyperpigmentary effect in melan-a cells. 
(A) (B) (C) 
2. Results 
2.1. Effects of the Chemical Compounds on Signaling Protein Expression Levels in Melan-a Cells 
The effects of 4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol on the protein expression level of 
several signaling pathways were shown in Figure 2. The concentrations of these compounds applied in 
our experiments were the effective concentrations to induce hypopigmentation in melan-a cells without 
causing cytotoxicity. Regarding the Western blot analysis on the effects of the chemical compounds on 
the PKA pathway (Figure 2A), it could be observed that 4-ethylresorcinol and 4-ethylphenol exhibited 
inhibitory effects on TRP-2 expression and 1-tetradecanol inhibited the expression of tyrosinase  
at higher concentration. The quantifications of the observations were shown in Figure 2B,C. Other proteins 
in the same pathway showed no obvious alteration in the presence of the three compounds. As shown 
in Figure 2D, expressions of the proteins in the p38 MAPK pathway, PI3K pathway and ERK pathway 
remained unchanged under the effect of the compounds. 
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Figure 2. (A) Western blot analysis on the effects of 4-ethylresorcinol, 4-ethylphenol  
and 1-tetradecanol on the protein expression level of PKA pathway. β-actin was used  
as a control for the system; Graphical presentation of the effects of 4-ethylresorcinol,  
4-ethylphenol and 1-tetradecanol on tyrosinase (B) and TRP-2 (C) protein expression. The 
densitometry of tyrosinase and TRP-2 protein expression was analyzed by AlphaEaseFC 
software (Alpha Innotech Corporation, San Leandro, CA, USA) and presented in a graphical 
expression. The quantified densitometry was expressed as percentage of control. **, p < 0.01 
when compared to control using one-way Analysis of Variance (ANOVA) followed by 
Dunnett’s test; (D) Western blot analysis on the effects of 4-ethylresorcinol, 4-ethylphenol 
and 1-tetradecanol on the protein expression level of p38 MAPK pathway, PI3K pathway 
and ERK pathway. ETR, 4-ethylresorcinol; ETP, 4-ethylphenol; TET, 1-tetradecanol; 
PKA, protein kinase A; CREB, cAMP response element binding protein; MITF, 
microphthalmia-associated transcription factor; TRP, tyrosinase-related protein; MAPK, 
mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; GSK, glycogen 
synthase kinase; MEK, MAPK kinase; ERK, extracellular signal-regulated kinase; RSK, 
ribosomal S6 kinase. 
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Figure 2. Cont. 
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2.2. Effects of the Chemical Compounds on Gene Expression Level in Melan-a Cells 
The effects of 4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol on the mRNA expression levels 
of tyrosinase, TRP-1 and TRP-2 were shown in Figure 3A. It could be observed that 4-ethylresorcinol 
and 4-ethylphenol decreased TRP-2 gene expression at both concentrations. The quantification of  
the results was shown in Figure 3B. The established depigmenting agents arbutin, kojic acid and 
phenylthiourea (PTU) were used as controls, which showed no inhibition on the level of the TRP-2 
gene. Other genes of the same protein family, including tyrosinase and TRP-1, remained unchanged in 
their expression levels upon incubation with the three compounds and the controls. Moreover,  
1-tetradecanol did not alter the expression level of tyrosinase, TRP-1 and TRP-2 genes. 
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Figure 3. (A) Effects of 4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol on the mRNA 
expression of tyrosinase family genes. Actin was used as a control for the system. Arbutin, 
kojic acid and PTU were applied for reference; (B) Graphical presentation of the effects of 
4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol on the mRNA expression of TRP-2. 
The densitometry of TRP-2 gene expression was analyzed by AlphaEaseFC software 
(Alpha Innotech Corporation) and presented in a graphical expression. The quantified 
densitometry was expressed as percentage of control. **, p < 0.01 when compared to  
control using one-way ANOVA followed by Dunnett’s test. PTU, phenylthiourea;  
ETR, 4-ethylresorcinol; ETP, 4-ethylphenol; TET, 1-tetradecanol; TYR, tyrosinase;  
TRP, tyrosinase-related protein. 
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2.3. Effects of the Chemical Compounds on Cyclic Adenosine Monophosphate (cAMP) Level in  
Melan-a Cells 
The effects of 4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol on cAMP level in melan-a cells 
were shown in Figure 4A. Among the compounds, 1-tetradecanol exhibited the strongest inhibitory 
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effect (nearly 40% inhibition) on cAMP level at both concentrations. This is followed by 4-ethylresorcinol 
in which the inhibition percentage was about 25% at both concentrations. 4-Ethylphenol had approximately 
20% inhibition at high concentration. The common depigmenting agents arbutin, kojic acid and 
phenylthiourea (PTU) elicited less than 25% inhibition on cAMP level (Figure 4B). Kojic acid slightly 
augmented cAMP level when dosage increased. PTU produced only about 24% inhibition at high 
concentration and the concentration of PTU that elicited inhibition on cAMP level was much higher 
than those of the three chemical compounds. It is clear that the three chemical compounds had stronger 
attenuating effect on cAMP level than the controls. 
Figure 4. Effects of 4-ethylresorcinol, 4-ethylphenol, 1-tetradecanol (A); arbutin, kojic 
acid and PTU (B) on cAMP level in melan-a cells. The extent of cAMP level attenuation 
was expressed as percentage of control. Each data point presents mean ± SD from three 
independent experiments. *, p < 0.05 when compared to control using one-way ANOVA 
followed by Dunnett’s test. Arbutin, kojic acid and PTU were applied for reference.  
ETR, 4-ethylresorcinol; ETP, 4-ethylphenol; TET, 1-tetradecanol; PTU, phenylthiourea. 
(A) (B) 
2.4. Effects of the Chemical Compounds on Protein Kinase A (PKA) Activity in Melan-a Cells 
The effects of 4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol on the activity of PKA in melan-a 
cells were shown in Figure 5A. All three compounds exhibited different degrees of inhibition on the 
activity of PKA. They were able to attenuate PKA activity at about 30% and 20% at high and  
low concentrations respectively. 1-Tetradecanol at high concentration exerted the strongest inhibition 
on PKA activity among the three compounds, followed by 4-ethylresorcinol and 4-ethylphenol. The 
common depigmenting agents arbutin, kojic acid and PTU had less than 20% inhibition on PKA 
activity (Figure 5B). PTU had no marked inhibition while kojic acid showed small activation on PKA 
activity when its concentration increased. Thus, the inhibitory effects of the depigmenting agents on 
PKA activity were weaker than the three chemical compounds. 
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Figure 5. Effects of 4-ethylresorcinol, 4-ethylphenol, 1-tetradecanol (A); arbutin, kojic 
acid and PTU (B) on PKA activity in melan-a cells. The extent of PKA activity attenuation 
was expressed as percentage of control. Each data point presents mean ± SD from three 
independent experiments. *, p < 0.05; ***, p < 0.001 when compared to control using  
one-way ANOVA followed by Dunnett’s test. Arbutin, kojic acid and PTU were  
applied for reference. ETR, 4-ethylresorcinol; ETP, 4-ethylphenol; TET, 1-tetradecanol;  
PTU, phenylthiourea. 
(A) (B) 
2.5. Effects of the Chemical Compounds on Tyrosinase Enzyme Activity 
The inhibitory effects of the three compounds on tyrosinase activity of melan-a cells were depicted 
in Figure 6. 4-Ethylresorcinol was a control in which its IC50 was found to be 21.1 μM in our  
assay condition. The activity of tyrosinase remained unchanged after the incubation of 4-ethylphenol  
and 1-tetradecanol. 
Figure 6. Effects of 4-ethylphenol and 1-tetradecanol on tyrosinase activity of melan-a 
cells. The extent of enzyme inhibition was expressed as percentage of control. Each data 
point presents mean ± SD from three independent experiments. 4-Ethylresorcinol and kojic 
acid were applied for reference. 
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2.6. Effects of the Chemical Compounds on Lipid Peroxidation of Mouse Liver Microsome 
The antioxidative ability of the hypopigmentary compounds on 2,2'-azobis (2-amidinopropane) 
dihydrochloride (AAPH)-induced mouse liver microsome peroxidation was shown in Figure 7. The 
amount of colored complex decreased dose-dependently under the effect of 4-ethylresorcinol and  
4-ethylphenol with IC50 values of 38.4 and 234.6 μM respectively. The colored complex amount 
remained constant in the presence of 1-tetradecanol. Trolox was used as a positive control, and its IC50 
was found to be 8.6 μM in our assay condition. 
Figure 7. Effects of 4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol on lipid peroxidation 
inhibition. The extent of lipid peroxidation inhibition was expressed as percentage  
of control. Each data point presents mean ± SD from three independent experiments.  
***, p < 0.001 when compared to control using one-way ANOVA followed by Dunnett’s 
test. Trolox was applied for reference. 
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3. Discussion 
Based on the melanin production screening assay in our previous work [26], 4-ethylresorcinol,  
4-ethylphenol and 1-tetradecanol were found to possess hypopigmentary effects. In the present  
study, we aimed to elucidate the underlying hypopigmentary mechanisms of these compounds.  
All three compounds attenuated the protein expression levels of tyrosinase family proteins  
(Figure 2A). Reduction in protein expression may influence the cascade reaction of melanogenesis and 
lead to depigmentation. The inhibitory effects of 4-ethylresorcinol and 4-ethylphenol on TRP-2 
expression may suppress the tautomerization of dopachrome to DHICA [10], and the inhibition of  
1-tetradecanol on tyrosinase expression may restrain the conversion of tyrosine to DOPA [4]. 
Inhibitory effects of effective compounds on melanogenic protein expressions may be due to the 
abilities of the compounds to affect translation or induce degradation of the proteins [27]. These 
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possible factors contribute to the hypopigmentary effects of the compounds, since TRP-2 and 
tyrosinase control critical steps of melanin synthesis which takes place in the melanosomes of 
melanocytes. Further evidence is needed to delineate the precise mechanism of action of the compounds 
towards tyrosinase and TRP-2 expression. 
4-Ethylresorcinol, 4-ethylphenol and 1-tetradecanol have a hydroxyl group in common, they all exert 
inhibitory effects on tyrosinase family proteins. 4-Ethylresorcinol and 4-ethylphenol have high similarity 
within their chemical structures, which differ in one hydroxyl group only, and their high similarities 
may be the reason that they exerted similar effect on TRP-2. Although tyrosinase, TRP-1 and TRP-2 
belong to the same protein family, they do have variations in their protein structures [28–30], and 
inhibition on one of them does not mean all of them can be inhibited. This may elucidate the different 
inhibiting targets of the compounds. Another interesting finding from our present study is that the 
protein expression level of tyrosinase was increased under the effect of 4-ethylresorcinol (Figure 2B). 
Since 4-ethylresorcinol inhibited TRP-2 expression (Figure 2C) and attenuated melanin synthesis,  
its accentuating role on tyrosinase protein expression remains to be determined. Moreover, the three 
compounds had no obvious influence on the protein expression levels of p38 MAPK, PI3K and ERK 
pathways (Figure 2D). This provided opposite arguments for the compounds which verified that their 
depigmenting effects did not affect p38 MAPK, PI3K and ERK pathways. 
Since the compounds exerted effects on the expression of tyrosinase family proteins, their effects on 
the expression of tyrosinase family genes were examined. 4-Ethylresorcinol and 4-ethylphenol were 
found to attenuate the mRNA expression of TRP-2 (Figure 3A). When transcription of the TRP-2 gene 
was inhibited and the mRNA level was alleviated under the effect of the two compounds, it may 
modulate the TRP-2 protein production dogma by terminating subsequent translation and translational 
modification of TRP-2 protein. This inference was supported by the results from Western blot analysis 
which demonstrated the inhibitory effect of 4-ethylresorcinol and 4-ethylphenol on TRP-2 protein 
expression. Therefore, the underlying hypopigmentary mechanism of the two compounds turned out to 
be the inhibition at the transcriptional level of TRP-2. 
The effects of 4-ethylresorcinol and 4-ethylphenol were compared to those of the known depigmenting 
agents including arbutin, kojic acid and PTU. The two compounds showed significant attenuating 
effect on TRP-2 gene expression while the controls did not. Moreover, the two compounds did not 
affect the gene expression of tyrosinase and TRP-1 (Figure 3A). The same result occurred on the protein 
expression of tyrosinase and TRP-1 (Figure 2A). Among the tyrosinase family genes, only TRP-2 gene 
expression was inhibited; tyrosinase and TRP-1 gene expression remained unaffected by all the test 
compounds (Figure 3A). 4-Ethylresorcinol and 4-ethylphenol acted on TRP-2 effectively at both gene 
and protein levels. They attenuated TRP-2 gene expression at both concentrations, but down-regulated 
TRP-2 protein expression only at higher concentration, thus their effect on TRP-2 protein expression 
appeared to be dose-dependent. Furthermore, 1-tetradecanol, which has a chemical structure different 
from the other two compounds, did not affect the mRNA level of the tyrosinase family gene (Figure 3A), 
though it alleviated tyrosinase protein expression at higher concentration (Figure 2A). 1-Tetradecanol 
was able to attenuate tyrosinase protein expression, but it could not affect the transcription of tyrosinase 
gene, so the attenuation in tyrosinase protein expression was not due to attenuation in tyrosinase gene 
expression. It appeared that the hypopigmentary effect of 1-tetradecanol was limited to the translational 
level of tyrosinase. 
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4-Ethylresorcinol, 4-ethylphenol and 1-tetradecanol were found to attenuate cAMP level, with  
1-tetradecanol being the most potent, followed by 4-ethylresorcinol and 4-ethylphenol (Figure 4A). 
Moreover, the compounds exhibited stronger effects in decreasing cAMP amount than the common 
depigmenting agents did (Figure 4B). Although PTU could achieve similar effects with the 
compounds, its concentration was much higher than the tested compounds. On the other hand, PKA is 
a critical enzyme responsible for the regulation of numerous cellular pathways within cells [31]. It 
affects the activity of a number of signaling proteins along the melanogenic pathway. Our results 
showed that 4-ethylresorcinol, 4-ethylphenol and 1-tetradecanol were able to inhibit the PKA activity 
(Figure 5A). Among the three compounds, 1-tetradecanol had the strongest inhibition at high 
concentration, followed by 4-ethylresorcinol and 4-ethylphenol. The order of inhibitory ability was 
similar to that of the cAMP assay. The inhibition percentages of the compounds on PKA activity were 
higher than the common depigmenting agents (Figure 5B). 
The compounds were able to attenuate PKA activity after decreasing cAMP level. This is reasonable 
as PKA activation depends on cAMP. Our results confirmed that all three compounds inhibited PKA 
activity in a cAMP-dependent manner and their effects in attenuating cAMP level and PKA activity 
were stronger than that of the known depigmenting agents. Although the compounds attenuated cAMP 
amount and PKA activity, the protein expression of the subsequent signaling proteins in the pathway, 
CREB and MITF, remained unchanged under the influence of the compounds (Figure 2A). As a result, 
the effect of the three compounds on cAMP and PKA activity may contribute to hypopigmentation 
indirectly through other pathways as cAMP is a common second messenger of many signaling 
cascades. Our experimental findings corroborated that the compounds acted on cAMP and PKA, the 
compounds also acted on tyrosinase and TRP-2 which are downstream proteins that participate in the 
pathway cascade initiated by PKA [16], thus it is believed that the compounds commonly affected the 
PKA pathway. 
Tyrosinase is the rate-limiting enzyme of melanogenesis. The enzyme assay of tyrosinase is 
convenient and efficient, and is commonly used as a screening tool in pigmentation research. Many 
compounds have been found to inhibit tyrosinase activity [32–37]. The competitive inhibition of  
4-ethylresorcinol towards tyrosinase was reported previously [35]. Our tyrosinase assay elucidates that 
known tyrosinase inhibitors (such as kojic acid) might take time to attain their effects in clinical 
conditions and their degree of persistency could be revealed. 
The discrepancies between 4-ethylresorcinol and 4-ethylphenol in terms of their inhibitory actions 
on tyrosinase may be due to different numbers and positions of functional groups on the benzene ring.  
4-Ethylresorcinol possesses two hydroxyl groups at para (p) and ortho (o) positions, respectively. The 
compound is electron-rich, as electron delocalization occurs between lone pair electrons of the 
phenoxyl oxygen and π electrons in the benzene ring. This may allow the compound to interact with 
the copper ion active site and interfere with the activity of tyrosinase [38]. 4-Ethylphenol lacks a 
hydroxyl group at position o of the benzene ring when compared to 4-ethylresorcinol. Its electron 
density was lower than 4-ethylresorcinol during electron delocalization, so it could barely interact with 
the active site of tyrosinase, and thus inhibition was not possible. Hence, the o position hydroxyl group 
is essential for the inhibition of tyrosinase activity. Since the hydroxyl group has electron-donating 
properties, more hydroxyl groups in 4-ethylresorcinol compared with 4-ethylphenol, resulted in greater 
inhibitory effects; this showed the significance of the number of hydroxyl groups in tyrosinase 
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inhibition [39]. 1-Tetradecanol does not have a benzene ring structure, and though it contains a 
hydroxyl group, electron delocalization cannot occur without π electrons. It was not electron-dense 
enough to interact with tyrosinase; this may explain its ineffectiveness towards tyrosinase inhibition. 
Many previous studies only tested the effect of chemicals on mushroom tyrosinase inhibition  
and chemicals with positive effect are regarded as potential whitening agents. In fact, results from 
mushroom tyrosinase screening are preliminary which requires confirmation by cell-based methods,  
as some hypopigmentary compounds may not be tyrosinase inhibitors, for example 4-ethylphenol  
and 1-tetradecanol (Figure 6). The advantage of our melan-a cell screening system over the mushroom 
tyrosinase screening method is that melan-a mimics a high hyperpigmentary condition in normal skin 
devoid of hormonal stimulation; thus the screened chemicals with positive effects have ensured ability 
to attenuate melanin production for further in vivo study. 
Depigmenting agents with antioxidative abilities are also particularly ideal because oxidation can 
bring about an increase in the degree of hyperpigmentation. When there is cumulative UV exposure, free 
radicals are produced within cells owing to induction of lipid peroxidation of skin cell membrane [36]. 
The situation may accelerate melanogenesis, as melanin can be synthesized by autooxidation of 
metabolites independent of tyrosinase family enzymes. Searching for depigmenting agents that play a 
role as an antioxidant at the same time helps to scavenge any free radicals present in skin cells. This 
would thereby attenuate the metabolite autooxidation which initiates subsequent melanin formation, and 
terminates free radical oxidation of cell membranes that leads to post-inflammatory hyperpigmentation and 
cell aging [40]. The antioxidant ability of the compounds was assessed by the mouse liver microsome lipid 
peroxidation inhibition assay. In this assay, mouse liver microsome acting as a lipid source is oxidized by 
the oxidant AAPH. Once oxidation takes place, lipid peroxides and malonyldialdehyde (MDA) are 
produced as a result of lipid peroxidation [41,42]. 
4-Ethylresorcinol and 4-ethylphenol attenuated the production of MDA complex in a dose-dependent 
manner (Figure 7), suggesting that 4-ethylresorcinol and 4-ethylphenol were antioxidants as they were 
able to scavenge AAPH-induced radicals and terminate chain reaction propagation of lipid peroxidation. 
Among the two compounds, 4-ethylresorcinol was a better radical scavenger and chain terminator than 
4-ethylphenol. Variation in antioxidative effect of the two compounds may be attributed to the number 
and position of the functional groups [43]. 4-Ethylresorcinol was a stronger antioxidant as it has  
one more hydroxyl group than 4-ethylphenol; it was able to form phenoxyl radical more readily than  
4-ethylphenol due to stronger resonance. This allowed it to interact with free radicals and stop 
oxidation propagation [44]. For instance, 4-ethylresorcinol and 4-ethylphenol had IC50 values higher 
than that of the positive control trolox, an effective antioxidant. 1-Tetradecanol lacked antioxidant 
activity, perhaps due to its linear structure, which was unable to form phenoxyl radicals to interact  
with the free radicals. As the oxidation product in this assay system could hardly be detected at minute 
quantities, higher concentrations of lipid sources and oxidants had to be applied during incubations; 
thus higher concentrations of compounds were required to reach the threshold of antioxidative effect. 
Therefore, the compounds that possessed antioxidative effects in this assay might be effective at low 
concentrations when the amount of lipid source and oxidant are lower in the cellular condition. 
The results of our present mechanistic study indicated that 4-ethylresorcinol is more effective in 
inhibiting melanin synthesis when compared to the other two compounds [26]. 4-Ethylresorcinol was 
able to attenuate mRNA and protein expression of TRP-2 (Figures 2A and 3A) and inhibit tyrosinase 
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activity [35], which probably overrode the effect of elevated protein expression of tyrosinase (Figure 2A). 
It also possessed antioxidative effects by inhibiting lipid peroxidation (Figure 7). These underlying 
mechanisms in different aspects render 4-ethylresorcinol with good anti-melanogenic advantages over 
4-ethylphenol and 1-tetradecanol; 4-ethylphenol only attenuated mRNA and protein expression of 
TRP-2 (Figures 2A and 3A), and possessed antioxidative effect (Figure 7), while 1-tetradecanol was only 
effective at the post-transcriptional level by attenuating protein expression of tyrosinase (Figure 2A) 
without inhibiting tyrosinase catalytic activity (Figure 6). 
4. Experimental Section 
4.1. Materials 
Apparatus for Western blot analysis was purchased from Bio-Rad (Hercules, CA, USA), except the 
film exposure cassette was from Amersham Biosciences Corporation (Piscataway, NJ, USA). Primary 
antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), Invitrogen 
Corporation (Carlsbad, CA, USA) and Cell Signaling Technology, Inc. (Danvers, MA, USA). Secondary 
antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz). Trizol was purchased 
from Invitrogen Corporation (Carlsbad). RT system was purchased from Promega (Madison, WI, USA). 
PCR machine was the product of Takara Bio Inc. (Otsu, Shiga, Japan). NanoDrop 2000c 
spectrophotometer for nucleic acid measurement was purchased from Thermo Scientific (Wilmington, 
DE, USA). The cAMP EIA kit was purchased from Cayman Chemical Company (Ann Arbor, MI, 
USA). Bio-Rad protein dye was purchased from Bio-Rad (Hercules). The PKA kinase activity kit was 
purchased from Enzo Life Sciences Inc. (Farmingdale, NY, USA). DOPA was purchased from  
Sigma–Aldrich (St. Louis, MO, USA). Other chemicals used in the study were purchased from  
Sigma–Aldrich (St. Louis) and USB (Cleveland, OH, USA). 
4.2. Cell Culture 
Melan-a is a copiously pigmented, immortalized non-tumorigenic mouse melanocyte cell line 
established from normal epidermal melanoblasts of embryos of inbred C57BL mice. Melan-a cells 
were grown in RPMI1640 medium supplemented with 10% FBS, 100 μg/mL streptomycin, 50 U/mL 
penicillin and 200 nM tetradecanoyl phorbol acetate (TPA) and incubated at 37 °C in a 5% CO2 and 
95% air humidified atmosphere. When cells were incubated with the chemical compounds, 20 nM 
TPA was used in the incubation medium for maintenance of cell growth [26]. 
4.3. Western Blot Analysis 
4.3.1. Preparation of Cell Lysates 
After five days of continuing incubation with chemical compounds, the culture medium was discarded 
from the 12-well plate, the melan-a cells were washed twice with phosphate buffered saline (PBS). 
Then 100 μL trypsin was added to each well and the plate was incubated at 37 °C for 10 min. 
Trypsinization was stopped by adding 100 μL of medium to each well, and the cells were scraped and 
collected in microtubes. The microtubes were centrifuged at 2000× g for 3 min, and the cell pellets 
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were retained for each sample. All pellets were resuspended with lysis buffer containing 50 mM Tris 
base (pH 7.5), 0.1 M sodium chloride (NaCl), 5 mM EDTA, 67 mM sodium pyrophosphate, 1.5% 
Triton X-100, 0.2 mM sodium orthovanadate, 0.2 mM phenylmethylsulfonyl fluoride, 1 mM 
dithiothreitol, 4 μM leupeptin and 4 μg/mL aprotinin. The cells were lysed on ice for 30 min with 
repeated pipetting action and the lysates were centrifuged at 12,000× g for 15 min at 4 °C. The 
supernatant was transferred to another microtube, followed by adding loading buffer and the mixture 
was boiled at 100 °C for 15 min with gentle shaking [45,46]. 
4.3.2. Protein Assay 
The current protein assay protocol was a summarized modification of the Bio-Rad protein assay. 
Briefly, the protein dye was diluted to its working concentration and was filtered. Then 10 μL diluted 
samples, together with various concentrations of bovine serum albumin standards (0, 0.025, 0.05, 0.1, 
0.2, 0.4, 0.6 and 0.8 mg/mL) were transferred to a 96-well plate. After that, 200 μL diluted protein dye 
was added to each well and absorbance was read at 595 nm. 
4.3.3. Western Blot 
The cell lysates were loaded (70–80 μg/lane) and separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) with 4% stacking gel and 10% separating gel for 90 min. The gels, 
together with polyvinylidene fluoride (PVDF) membranes (Millipore Corporation, Billerica, MA, USA) 
which were presoaked in methanol, then in transfer buffer (25 mM Tris pH 8.3, 192 mM glycine  
and 20% methanol), were placed in a semi-dry transfer system (Bio-Rad, Hercules) and transferred for  
70 min. The membranes were then blocked for 1 h by 5% milk in Tris-buffered saline-Tween (TTBS) 
containing 20 mM Tris (pH 7.5), 0.8% NaCl and 0.1% Tween 20. After that, the membranes  
were incubated overnight with primary antibodies at 4 °C with constant shaking. The next day, the 
membranes were washed with TTBS and incubated with corresponding secondary antibodies for 1 h at 
room temperature with constant shaking, followed by another wash. Chemiluminescent horseradish 
peroxidase (HRP) substrate (Millipore Corporation, Billerica, MA, USA) was used for film development 
to visualize blotted images [45,47]. 
4.4. RT-PCR 
Total RNA was extracted from cells using Trizol solution according to the manufacturer’s 
instructions (Invitrogen Corporation, Carlsbad). RNA concentrations were measured by NanoDrop 
2000c spectrophotometer (Thermo Scientific). RT and PCR were performed by using 1 μg of total 
RNA as per the manufacturer’s protocol (Promega, Madison, WI, USA). The following oligonucleotide 
primers were applied in PCR: tyrosinase upstream 5'-GGC CAG CTT TCA GGC AGA GGT-3'; 
downstream 5'-TGG TGC TTC ATG GGC AAA ATC-3'; TRP-1 upstream 5'-GCT GCA GGA GCC 
TTC TTT CTC-3'; downstream 5'-AAG ACG CTG CAC TGC TGG TCT-3'; TRP-2 upstream 5'-GGA 
TGA CCG TGA GCA ATG GCC-3'; downstream 5'-CGG TTG TGA CCA ATG GGT GCC-3'; Actin 
upstream 5'-TGG AAT CCT GTG GCA TCC ATG AAA C-3'; downstream 5'-TAA AAC GCA GCT 
CAG TAA CAG TCC G-3'. The PCR reaction was cycled 25 times: 94 °C, 30 s; 56 °C, 30 s; 72 °C, 45 s. 
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PCR products were electrophoresed in 1% agarose gel, and the bands were visualized by a UV 
illuminator [48–50]. 
4.5. cAMP Assay 
cAMP assay was performed according to the manufacturer’s instructions (Cayman Chemical 
Company). Briefly, the cells were lysed on ice for 30 min with repeated pipetting action, and the 
lysates were centrifuged at 2000× g for 5 min at 4 °C. The supernatant was transferred to another 
microtube and diluted with EIA buffer in a 1:2 ratio. The cAMP concentrations of the samples were 
determined by the equation obtained from the calibration curve according to the protocol, and the 
results were expressed as percentage of control. 
4.6. The PKA Activity Assay 
The PKA activity assay was performed according to the manufacturer’s instructions (Enzo Life 
Sciences Inc., Farmingdale, NY, USA). Briefly, the cells were lysed on ice for 30 min with repeated 
pipetting action, and the lysates were centrifuged at 12,000× g for 15 min at 4 °C. The supernatant was 
transferred to another microtube. The average absorbance of blank was subtracted from the average 
absorbance of samples and controls. The corrected sample absorbance was divided by the corrected 
control absorbance at 450 nm and the results were expressed as the percentage of control. 
4.7. Tyrosinase Inhibition Assay 
The cell lysates, prepared from the lysis buffer as mentioned in Western blot analysis, were frozen 
and thawed for a few times and were then centrifuged at 12,000× g for 15 min at 4 °C. After that, 90 μL 
supernatant and 10 μL DOPA were added to each well of a 96-well plate. The plate was wrapped with 
aluminum foil to avoid light exposure and was incubated at 37 °C. Three days later, the plate was 
transferred to a microplate spectrophotometer (Sunrise, Tecan Group Ltd., Mannedorf, Switzerland), 
the absorbance was read at the wavelength of 475 nm [46]. The average absorbance of blank was 
subtracted from the average absorbance of samples and controls. The corrected sample absorbance was 
divided by the corrected control absorbance at 475 nm and the results were expressed as the percentage 
of control. 
4.8. Antioxidative Activity Assay 
4.8.1. Preparation of Mouse Liver Microsomes 
BALB/c mice were sacrificed by decapitation. Livers were excised and rinsed twice with 0.9% 
saline at 4 °C. All subsequent preparative procedures were carried out at 4 °C unless otherwise specified. 
Livers were then homogenized in 0.15 M potassium chloride (KCl). The amount of KCl added to liver 
was 3 mL/g. The homogenate was centrifuged at 10,000× g for 20 min at 4 °C. The supernatant was 
retained and centrifuged at 100,000× g for 1 h at 4 °C. The supernatant was discarded. The pellet was 
resuspended with KCl. The stock was stored at −20 °C after determination of protein concentration [51]. 
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4.8.2. Lipid Peroxidation Inhibition Assay 
Lipid peroxidation of mouse liver microsomes was produced by AAPH oxidation. The reaction 
mixture had a final volume of 400 μL containing PBS (pH 7.4), 10 mg/mL mouse liver microsome,  
0.5 mM EDTA, chemical compound and 10 mM AAPH. The mixtures were incubated at 37 °C for  
1 h with constant stirring. After incubation, 200 μL 20% trichloroacetic acid and 200 μL 0.8% 
thiobarbituric acid were added to each sample. The mixtures were heated for 20 min at 99 °C. They were 
then centrifuged at 3000× g for 5 min and 200 μL supernatant was transferred to a 96-well plate for 
measurement at a wavelength of 532 nm [52]. Net absorbance was calculated by subtraction of 
readings between samples and blanks without AAPH. The net sample absorbance was divided by the 
net control absorbance at 532 nm and the degree of lipid peroxidation for each sample was expressed 
as the percentage of control. 
4.9. Statistical Analysis 
Data were presented as mean ± SD. Comparison between treatment groups were carried out using 
one-way ANOVA followed by post hoc Dunnett’s test. Statistical analysis was conducted on a 
GraphPad Prism 4 computer program (GraphPad Software Inc., San Diego, CA, USA). Differences 
were considered significant when p < 0.05 and denoted as *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
5. Conclusions 
Taking all the results into consideration, it can be concluded that the hypopigmentary actions of the 
effective compounds mainly focus on regulating downstream proteins, tyrosinase and TRP-2, in the 
PKA pathway. The present study provides a better understanding of the melanogenic mechanism of a 
number of chemical compounds, and paves a way for further development of effective hypopigmentary 
agents into cosmetic products with skin whitening properties on a scientific basis. 
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